Tag: Viral entry

Approved by the FDA in 2003, enfuvirtide (Fuzeon) was the first HIV fusion inhibitor to be introduced, representing a new class of antiretroviral drugs. The mechanism of action of enfuvirtide involves a unique, extracellular approach to inhibit the fusion of the human immunodeficiency virus (HIV) with healthy host cells, thereby preventing viral replication.

Approved by the FDA in 2003, enfuvirtide was the first HIV fusion inhibitor, representing a new class of antiretroviral drugs. This innovative medication provides a crucial treatment option for individuals whose virus has developed resistance to other HIV therapies by targeting the viral entry process.